The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

BACKGROUND: Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder size and function. METHODS: Patients with advanced metastatic solid tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688238/
https://www.ncbi.nlm.nih.gov/pubmed/23679351
http://dx.doi.org/10.1186/1471-2407-13-242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688238/
https://www.ncbi.nlm.nih.gov/pubmed/23679351
http://dx.doi.org/10.1186/1471-2407-13-242

Ejemplares similares